Evidence map›Paper›PMID 35326637›Full record

ArticleCancers2022

Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in

Thibault Passeri, Ahmed Dahmani, Julien Masliah-Planchon, Adnan Naguez, Marine Michou, Rania El Botty, Sophie Vacher, Rachida Bouarich, André Nicolas, Marc Polivka and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Pharmacology and pharmacokinetics of tazemetostat.Cancer chemotherapy and pharmacology · 2024
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Frontiers in oncology · 2022
    Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Thibault PasseriLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, University of Paris Saclay, 75005 Paris, France.ORCID 0000-0003-4759-0389
Ahmed DahmaniLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, University of Paris Saclay, 75005 Paris, France.
Julien Masliah-PlanchonDepartment of Genetics, Institut Curie, University of Paris Saclay, 75005 Paris, France.
Adnan NaguezLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, University of Paris Saclay, 75005 Paris, France.
Marine MichouLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, University of Paris Saclay, 75005 Paris, France.
Rania El BottyLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, University of Paris Saclay, 75005 Paris, France.
Sophie VacherDepartment of Genetics, Institut Curie, University of Paris Saclay, 75005 Paris, France.ORCID 0000-0002-0042-6023
Rachida BouarichIntegrated Cancer Research Site, Institut Curie, 75005 Paris, France.
André NicolasDepartment of Tumor Biology, Institut Curie, 75005 Paris, France.
Marc PolivkaDepartment of Pathology, Lariboisière Hospital, Assistance Publique des Hôpitaux de Paris, University of Paris, UMR 1141 Inserm, 75010 Paris, France.
Coralie FranckDepartment of Genetics, Institut Curie, University of Paris Saclay, 75005 Paris, France.
Anne SchnitzlerDepartment of Genetics, Institut Curie, University of Paris Saclay, 75005 Paris, France.
Fariba NématiLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, University of Paris Saclay, 75005 Paris, France.ORCID 0000-0001-8879-7592
Sergio Roman-RomanDepartment of Translational Research, Institut Curie, University of Paris Saclay, 75005 Paris, France.
Franck BourdeautIntegrated Cancer Research Site, Institut Curie, 75005 Paris, France.
Homa Adle-BiassetteDepartment of Pathology, Lariboisière Hospital, Assistance Publique des Hôpitaux de Paris, University of Paris, UMR 1141 Inserm, 75010 Paris, France.
Hamid MammarProton Therapy Center, Institut Curie, 91400 Orsay, France.
Sébastien FroelichDepartment of Neurosurgery, Lariboisière Hospital, Assistance Publique des Hôpitaux de Paris, University of Paris, 75010 Paris, France.
Ivan BiècheDepartment of Genetics, Institut Curie, University of Paris Saclay, 75005 Paris, France.
Didier DecaudinLaboratory of Preclinical Investigation, Translational Research Department, Institut Curie, University of Paris Saclay, 75005 Paris, France.
Université Paris-Saclay · FRInstitut Curie · FRInserm · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chordomas are rare neoplasms characterized by a high recurrence rate and a poor long-term prognosis. Considering their chemo-/radio-resistance, alternative treatment strategies are strongly required, but their development is limited by the paucity of relevant preclinical models. Mutations affecting genes of the SWI/SNF complexes are frequently found in chordomas, suggesting a potential therapeutic effect of epigenetic regulators in this pathology. Twelve PDX models were established and characterized on histological and biomolecular features. Patients whose tumors were able to grow into mice had a statistically significant lower progression-free survival than those whose tumors did not grow after in vivo transplantation (

Indexed as

chordomaEZH2 inhibitornext-generation sequencingpatient-derived xenograftstargeted therapy

Identifiers

PMID35326637
PMCPMC8946089
OpenAlexW4220772782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.